FDA Approves CLL Treatment under Project Orbis

FDA Approves CLL Treatment under Project Orbis

The FDA granted supplemental approval to Calquence (acalabrutinib), atreatment for adults with chronic lymphocytic leukemia (CLL) or small lyphocytic lymphoma (SLL). This approval was part of Project Orbis, a collaboration among the FDA, the Australian Therapeutic Goods Administration, and Health Canada, marking the second approval under the program. As a global provider of clinical packaging and courier services, Yourway has a breadth of knowledge of international regulations and supports more initiatives to harmonize regulations across nations.

Back to Index

Upcoming Event


August 24-26, 2020
Brussels, Belgium



The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?